New possibilities of vildagliptin administration as part of combinations of three drugs

Abstract

New combinations of three agents extend the treatment options for vildagliptin use; their advantages are based mainly on the low risk of hypoglycaemia and the absence of the necessity to increase the doses of drugs that cause hypoglycaemias.

Keywords

• Type 2 diabetes mellitus
• DPP-4 inhibitors
• vildagliptin
• metformin
• sulfonylurea derivates
• insulin